“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Ranolazine Extended release tablet 500mg
Oncology is the future segment of the industry. With rising incidence of cancer in India and richest pipeline of new products makes this segment very attractive for our company, which is futuristic in planning its growth plans. In oncology, we have identified and launched molecules for two of the most common cancers seen in India i.e. breast cancer and Colorectal.
Lupin Oncology has launched two unique brands ieGenexol-PM (Nanoparticle Paclitaxel) and Luporal (Tegafur + Uracil) by tie-ups with Korean and Taiwanese companies.
We are constantly striving hard to connect with companies overseas for in-licensing opportunities to bring newer therapies that can improve survival of the patients in India. We also believe in launching the common protocol therapies at cost-effective prices and hence have launched LUPINIB (Imatinib) at the cost effective price compared to the other brands in the segment.
Lupin Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil. Since then we have received more than a hundred FDA approvals.
>> Find out More
Lupin’s specialty business in the U.S. was established in 2003 with the reintroduction of SUPRAX (cefixime) oral suspension, and marketing a range of products across therapeutic categories, including ANTARA® (fenofibrate) and METHERGINE® (methylergonovine maleate), as well as launching InspiraChamber® (valved holding chamber), and most recently, SOLOSEC® (secnidazole). While our search for cutting-edge medicines to improve the treatment of special conditions is never over, we are currently focused on women’s health, and also pursuing growth opportunities in other areas of unmet needs.
>> Find out More
Lupin is recognized as a leading manufacturer of cephalosporin API's, with FDA approval to manufacture complex oral and injectable cephalosporins.